Clear cell renal cell carcinoma (ccRCC) is the most prevalent and lethal subtype of renal cell carcinoma (RCC), characterized by a poor prognosis and a high likelihood of distant metastasis.

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...

Side effects from targeted therapies depend on the drug used but may include diarrhea, fatigue, nausea, vomiting, and others. Renal cell carcinoma has different subtypes, with clear cell being the ...

Dr. David A Braun delved into detail on the molecular factors driving exceptional responses to immunotherapy in metastatic ...

At this year’s ASCO Annual Meeting, researchers presented detailed findings concerning biomarkers and rare subtypes of renal ...

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...

(UroToday.com) The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Brian Shuch discussing results from ZIRCON, a phase 3 ...

According to the American Cancer Society (ACS), about 81,800 people in the U.S. are expected to be diagnosed with kidney and renal pelvic cancers in 2023. The most common type is called renal cell ...

The following is a summary of “Clinical significance and pro-oncogenic function of DBF4 in clear cell renal cell carcinoma,” published in the January 2025 issue of Urology by Chen et al. Clear cell ...

January 14, 2025 Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma. January 14, 2025 Sitravatinib in combination with nivolumab plus ipilimumab in patients ...